Prospective validation of prognostic and diagnostic syncope scores in the emergency department

du Fay de Lavallaz, Jeanne, Badertscher, Patrick, Nestelberger, Thomas, Isenrich, Rahel, Miró, Òscar, Salgado, Emilio, Geigy, Nicolas, Christ, Michael, , Than, Martin, Martin-Sanchez, F. Javier, Bustamante Mandrión, José, Di Somma, Salvatore, Peacock, W. Frank, Kawecki, Damian, Boeddinghaus, Jasper, Twerenbold, Raphael, Puelacher, Christian, Wussler, Desiree, Strebel, Ivo, Keller, Dagmar I., Poepping, Imke, Kühne, Michael, Mueller, Christian, Reichlin, Tobias, Giménez, Maria Rubini, Walter, Joan, Kozhuharov, Nikola, Shrestha, Samyut, Mueller, Deborah, Sazgary, Lorraine, Morawiec, Beata, Muzyk, Piotr, Nowalany-Kozielska, Ewa, Freese, Michael, Stelzig, Claudia, Meissner, Kathrin, Kulangara, Caroline, Hartmann, Beate, Ferel, Ina, Sabti, Zaid, , Hawkins, Tracey, Rentsch, Katharina, von Eckardstein, Arnold, Buser, Andreas, Kloos, Wanda, Lohrmann, Jens, & Osswald, Stefan (2018) Prospective validation of prognostic and diagnostic syncope scores in the emergency department. International Journal of Cardiology, 269, pp. 114-121.

View at publisher

Description

Background: Various scores have been derived for the assessment of syncope patients in the emergency department (ED) but stay inconsistently validated. We aim to compare their performance to the one of a common, easy-to-use CHADS 2 score.

Methods: We prospectively enrolled patients ≥ 40 years old presenting with syncope to the ED in a multicenter study. Early clinical judgment (ECJ) of the treating ED-physician regarding the probability of cardiac syncope was quantified. Two independent physicians adjudicated the final diagnosis after 1-year follow-up. Major cardiovascular events (MACE) and death were recorded during 2 years of follow-up. Nine scores were compared by their area under the receiver-operator characteristics curve (AUC) for death, MACE or the diagnosis of cardiac syncope.

Results: 1490 patients were available for score validation. The CHADS 2 -score presented a higher or equally high accuracy for death in the long- and short-term follow-up than other syncope-specific risk scores. This score also performed well for the prediction of MACE in the long- and short-term evaluation and stratified patients with accuracy comparative to OESIL, one of the best performing syncope-specific risk score. All scores performed poorly for diagnosing cardiac syncope when compared to the ECJ.

Conclusions: The CHADS 2 -score performed comparably to more complicated syncope-specific risk scores in the prediction of death and MACE in ED syncope patients. While better tools incorporating biochemical and electrocardiographic markers are needed, this study suggests that the CHADS 2 -score is currently a good option to stratify risk in syncope patients in the ED. Trial registration: NCT01548352

Impact and interest:

17 citations in Scopus
16 citations in Web of Science®
Search Google Scholar™

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

ID Code: 200340
Item Type: Contribution to Journal (Journal Article)
Refereed: Yes
ORCID iD:
Greenslade, Jaimiorcid.org/0000-0002-6970-5573
Measurements or Duration: 8 pages
Keywords: Diagnosis, Emergency department, Scores, Syncope
DOI: 10.1016/j.ijcard.2018.06.088
ISSN: 0167-5273
Pure ID: 57681549
Funding Information: This work was supported by research grants from the Swiss National Science Foundation ( 138403 ), the Swiss Heart Foundation , the Cardiovascular Research Foundation Basel (Switzerland) , the University Basel (Switzerland) , BRAHMS , Singulex , the University Hospital Basel (Switzerland) , and the Emergency Medicine Foundation (Australia) ( EMSS-402R21-2014 ). Professor Mueller has received research support from the Swiss National Science Foundation, the Swiss Heart Foundation, the European Union, the KTI, the Cardiovascular Research Foundation Basel, Abbott, Astra Zeneca, Biomerieux, Beckman Coulter, BG medicine, BRAHMS, Critical Diagnostics, Radiometer, Roche, Siemens, and Singulex, as well as speaker/consulting honoraria or travel support from Abbott, Alere, Bayer, BMS, Boehringer Ingelheim, BRAHMS, Cardiorentis, Daiichi Sankyo, Novartis, Roche, Sanofi, Siemens, and Singulex. Dr. Twerenbold reports grants from the Swiss National Science Foundation (Grant No P300PB_167803), the University Hospital Basel, the University of Basel and the Cardiovascular Research Foundation Basel, personal fees from Roche Diagnostics, Abbott Diagnostics, Siemens, Singulex and Brahms, outside the submitted work. Dr. Than reports grants and personal fees from Abbott, grants and personal fees from Alere, grants from Beckman, grants and personal fees from Roche, outside the submitted work.
Copyright Owner: 2018 Elsevier B.V.
Copyright Statement: This work is covered by copyright. Unless the document is being made available under a Creative Commons Licence, you must assume that re-use is limited to personal use and that permission from the copyright owner must be obtained for all other uses. If the document is available under a Creative Commons License (or other specified license) then refer to the Licence for details of permitted re-use. It is a condition of access that users recognise and abide by the legal requirements associated with these rights. If you believe that this work infringes copyright please provide details by email to qut.copyright@qut.edu.au
Deposited On: 25 May 2020 05:26
Last Modified: 01 Mar 2024 20:47